Cargando…
Investigational Anti–Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?
Antiarrhythmic drugs remain the mainstay therapy for patients with atrial fibrillation (AF). A major disadvantage of the currently available anti-AF agents is the risk of induction of ventricular proarrhythmias. Aiming to reduce this risk, several atrial-specific or -selective ion channel block appr...
Autor principal: | Burashnikov, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Journal of Cardiovascular Pharmacology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641178/ https://www.ncbi.nlm.nih.gov/pubmed/33165131 http://dx.doi.org/10.1097/FJC.0000000000000892 |
Ejemplares similares
-
Inotropes and Inodilators for Acute Heart Failure: Sarcomere Active Drugs in Focus
por: Nagy, László, et al.
Publicado: (2014) -
Targeting β(3)-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade
por: Cannavo, Alessandro, et al.
Publicado: (2017) -
Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications
por: Altenberger, Johann, et al.
Publicado: (2018) -
Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice
por: Guarracino, Fabio, et al.
Publicado: (2018) -
FDA review times for new drugs in ophthalmology
por: Carpenter, Michelle A., et al.
Publicado: (2020)